Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd., a major player in the pharmaceutical industry, has detailed the composition of its 11-member board of directors, alongside the allocation of roles within five key Board committees. The announcement clarifies the structure of leadership, with Mr. WU Yifang serving as the chairman and representation across executive, non-executive, and independent directors in various committees focused on strategy, audit, nomination, remuneration, appraisal, and environmental, social and governance issues.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
